Neurotrack is a digital health company organized around development of non-invasive cognitive health assessment tools designed to enable earlier and more effective evaluation of patients who may be at risk for cognitive decline. Participant in what is defined as the "virtual' component of JLabs, the firm is structured around advancing research of treatments for cognitive diseases - to include Alzheimer's. Anchored in technology licensed exclusively out of Emory University, Neurotrack is developing behavioral tests for Alzheimer's disease risk or mild cognitive impairment prior to clinical disease diagnosis, A longitudinal study undetaken by the firm suggests the test is able to predict Alzheimer's with a high level of accuracy as much as three to four years prior to a clinical diagnosis. Neuroteck's lead product is Imprint -Check-Up, a five-minute test that uses eye-tracking technology to assess cognitive decline before symptoms appear. The early diagnosis of memory loss is critical for prevention of cognitive decline. Hence, focus has been on trying to predict memory loss before it starts. Neurotrack also offers a Cognitive Health Program providing users with tools and advice to make lifestyle changes scientifically proven to reduce the risk of cognitive decline and diseases like Alzheimers
